Trial Profile
A randomised, double-blind, multicentre phase ii trial to evaluate the biological effects, safety and pharmacokinetics of single agent zd1839 (iressatm) and zd1839 in combination with anastrozole (arimidex®) in patients with primary breast cancer
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 15 Jun 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Anastrozole
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms Coombes Study 77
- 05 Nov 2010 New trial record.